BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) | RFA MH 21 175

FAQs: NIH BRAIN Initiative R01 (RFA-MH-21-175)

What is the title and funding opportunity number for this grant?

The opportunity is titled "Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (Clinical Trial Not Allowed)" under the NIH BRAIN Initiative. The funding opportunity number is RFA-MH-21-175.

What grant mechanism is being used?

This opportunity uses the NIH R01 research project grant mechanism.

Which agency is offering this funding opportunity?

The funding opportunity is offered by the National Institutes of Health (NIH).

Is this a new announcement or a reissue?

This announcement is a reissue of an earlier solicitation, RFA-MH-19-136.

What is the main purpose of this BRAIN Initiative R01?

The purpose is to accelerate the development of new neurotechnology tools that enable researchers to analyze brain circuits in much greater detail and better understand how different brain cells interact to produce normal brain function.

What kind of projects is NIH trying to encourage with this opportunity?

NIH is aiming to support ambitious tool development that goes beyond incremental upgrades. The intent is to create tools that meaningfully expand what researchers can measure, manipulate, or map within the nervous system.

What does "cell-type specificity" mean in the context of this announcement?

In this program, cell-type specificity means the proposed tool or technology should be able to selectively access or act on particular neuronal or glial populations, rather than treating the brain as uniform tissue.

What does "circuit-level specificity" mean in the context of this announcement?

Circuit-level specificity refers to methods that can target particular pathways and connections in the brain, enabling study or manipulation of defined circuits rather than broad, non-specific regions.

Are applicants required to include a validation plan?

Yes. The announcement emphasizes that strong, well-designed validation plans are required. A competitive application should describe how the tool will be tested and demonstrated to work as intended.

What kinds of validation outcomes are expected?

Applications are expected to show evidence that the tool improves precision, sensitivity, and/or usability compared with established approaches, and that it produces interpretable, useful data for neuroscience research.

Does NIH prefer tools that are only theoretical, or tools demonstrated to work in practice?

The solicitation emphasizes real-world utility. The goal is not just to propose a new idea, but to demonstrate that the tool works and can be used effectively for neuroscience research.

What types of strategies are of interest (genetic vs. non-genetic)?

NIH highlights interest in both genetic and non-genetic strategies, particularly approaches for delivering genes, proteins, and chemicals to targeted cells with improved precision and sensitivity.

What delivery-related challenges does the program aim to address?

The program is interested in tools that can overcome longstanding delivery, specificity, or signal-to-noise limitations, including better access to targeted cell types or circuits than current methods provide.

Is there a preference for tools that work across multiple species?

Yes. The announcement signals a preference for tools that are generalizable across multiple species or model organisms, rather than being narrowly limited to a single species.

Why does the opportunity emphasize cross-species generalizability?

Based on the announcement language, the intent is broad impact across basic neuroscience and easier adoption by labs working in different systems, which can also support more effective comparisons of results.

What is meant by "breaking technical barriers" or "step-change" advances?

This program encourages projects that represent substantial capability advances, such as markedly improved targeting specificity, more reliable access to hard-to-reach circuits, better sensitivity for measuring cell-type-specific activity or interactions, or new modalities that expand what can be probed in intact circuits.

Are clinical trials allowed under this opportunity?

No. Clinical trials are not allowed under this specific funding opportunity.

What is the application focus: basic neuroscience tools or clinical research tools?

Based on the description provided, the focus is on developing and validating research tools for probing cell-specific and circuit-specific processes in the brain, with clinical trials explicitly not allowed.

What is the opportunity creation date and the original closing date?

The opportunity was created on 2021-04-27, and the original closing date listed is 2023-05-08.

Are the award ceiling and expected number of awards provided?

No. The award ceiling and the expected number of awards are not specified in the provided source details.

What CFDA program numbers are associated with this opportunity?

The opportunity is associated with multiple CFDA program numbers: 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, and 93.867.

Who is eligible to apply?

Eligibility is broad and includes many domestic applicants such as state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations (with or without 501(c)(3) status); for-profit organizations (other than small businesses) and small businesses; and other entities.

Are minority-serving institutions and similar organizations eligible?

Yes. The announcement explicitly includes Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs) as eligible applicant categories.

Are faith-based or community-based organizations eligible to apply?

Yes. Faith-based or community-based organizations are explicitly listed among eligible applicant categories.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are explicitly included among eligible applicant categories.

Are tribal governments other than federally recognized tribes eligible?

Yes. The eligibility list explicitly includes tribal governments other than federally recognized entities.

Are foreign (non-U.S.) organizations eligible to apply?

Yes. The eligibility list explicitly includes non-U.S. (foreign) organizations.

Are eligible federal agencies able to apply?

Yes. Eligible federal agencies are explicitly included among the eligible applicant categories.

Does the opportunity specify that the proposed tool must target neurons only?

No. The description states that tools may selectively access particular neuronal or glial populations, indicating that non-neuronal brain cell types are within scope.

Does the announcement prioritize precision and sensitivity?

Yes. The program description repeatedly emphasizes improved precision and sensitivity, including improved targeting specificity and better signal-to-noise performance compared with existing approaches.

Does NIH require that proposed tools be broadly usable by the neuroscience community?

The opportunity expresses a preference for broadly applicable, generalizable methods and emphasizes real-world utility and adoption across multiple species/model organisms, which aligns with wide usability for neuroscience research.